Literature DB >> 2827815

The Corfu delta beta zero thalassemia: a small deletion acts at a distance to selectively abolish beta globin gene expression.

A E Kulozik1, N Yarwood, R W Jones.   

Abstract

The Corfu delta beta zero thalassemia is characterized by the clinical picture of thalassemia intermedia. In the homozygous state there is a complete absence of hemoglobin (Hb) A and Hb A2 and a high level of Hb F. A DNA fragment containing the gamma and beta globin genes has been cosmid cloned, and the deletion breakpoint region, the beta globin gene and the promoter regions of the gamma globin genes sequenced. The deletion removes 7,201 base pairs (bp) containing part of the delta globin gene and sequences upstream. The beta globin gene contains a G----A mutation at IVS 1 position 5. The gamma globin gene promoters are normal. Analysis of the transcription of the mutated beta globin gene in transfected HeLa cells shows that normal message is produced at a level of approximately 20% compared with a normal gene, the remaining 80% being spliced at cryptic sites in exon 1 and intron 1. This indicates that the mutation in the beta globin gene is not the sole cause of the absence of Hb A in Corfu delta beta zero thalassemia. It is concluded that the 7.2 kilobase (kb) of deleted DNA contains sequences necessary for the normal activation of the beta globin gene. Possible mechanisms for the effect of the deletion on the expression of beta and gamma globin genes are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827815

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Beta-thalassaemia: molecular pathogenesis and clinical variability.

Authors:  A E Kulozik
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

Review 2.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 3.  Fetal hemoglobin in sickle cell anemia.

Authors:  Idowu Akinsheye; Abdulrahman Alsultan; Nadia Solovieff; Duyen Ngo; Clinton T Baldwin; Paola Sebastiani; David H K Chui; Martin H Steinberg
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

4.  Short, direct repeats at the breakpoints of deletions of the retinoblastoma gene.

Authors:  S Canning; T P Dryja
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Thalassemia intermedia: compound heterozygous beta zero/beta(+)-thalassemia and co-inherited heterozygous alpha(+)-thalassemia.

Authors:  A E Kulozik; E Kohne; E Kleihauer
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

6.  Evidence for a bigenic chromatin subdomain in regulation of the fetal-to-adult hemoglobin switch.

Authors:  Hugues Beauchemin; Marie Trudel
Journal:  Mol Cell Biol       Date:  2008-12-29       Impact factor: 4.272

Review 7.  The molecular basis of β-thalassemia.

Authors:  Swee Lay Thein
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

Review 8.  Animal models of β-hemoglobinopathies: utility and limitations.

Authors:  Bradley McColl; Jim Vadolas
Journal:  J Blood Med       Date:  2016-11-04

Review 9.  Genomic approaches to identifying targets for treating β hemoglobinopathies.

Authors:  Duyen A Ngo; Martin H Steinberg
Journal:  BMC Med Genomics       Date:  2015-07-29       Impact factor: 3.063

10.  Heterozygosity of the Complex Corfu δ0β+ Thalassemic Allele (HBD Deletion and HBB:c.92+5G>A) Revisited.

Authors:  Christos Kattamis; Myrto Skafida; Polyxeni Delaporta; Christina Vrettou; Joanne Traeger-Synodinos; Christalena Sofocleous; Antonis Kattamis
Journal:  Biology (Basel)       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.